Product
Experimental
Aliases
Experimental drug
4 clinical trials
4 indications
Indication
COVID-19Indication
Colorectal cancerIndication
Colorectal CancerIndication
Resistant HypertensionClinical trial
A Prospective, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blind Trial to Evaluate the Clinical Efficacy of NanoManganese® on Top of Standard of Care, in Adult Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19)Status: Terminated, Estimated PCD: 2022-10-04
Clinical trial
An Open-label, Multi-centered, Two-stage Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine in the First Line Treatment of Advanced mCRC Patients Unfit for Intense TherapyStatus: Not yet recruiting, Estimated PCD: 2026-01-01
Clinical trial
Chidamide+Sintilimab+Bevacizumab Versus Standard Second-Line Therapy of FOLFIRI+Bevacizumab in Subjects With Advanced Microsatellite Stable (MSS/pMMR) Colorectal Cancer Who Have Failed Oxaliplatin-Containing First-Line TherapyStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant HypertensionStatus: Active (not recruiting), Estimated PCD: 2024-07-02